<em>In&nbsp;vitro</em> effects of azide‑containing human CRP isoforms and oxLDL on U937‑derived macrophage production of atherosclerosis‑related cytokines

Jundi,Dania; Krayem,Imtissal; Bazzi,Samer; Karam,Marc

doi:10.3892/etm.2020.9185

In vitro effects of azide‑containing human CRP isoforms and oxLDL on U937‑derived macrophage production of atherosclerosis‑related cytokines

Authors:
- Dania Jundi
- Imtissal Krayem
- Samer Bazzi
- Marc Karam
View Affiliations

Affiliations: Department of Biology, University of Balamand, Kourah, P. O. Box 100 Tripoli, North Governorate, Lebanon
Published online on: September 4, 2020 https://doi.org/10.3892/etm.2020.9185
Article Number: 57

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Atherosclerosis is an inflammatory chronic disease of the arterial wall. Monomeric (m) and pentameric (p) C‑reactive protein (CRP) and oxidized low density lipoproteins (oxLDL) seem to affect the pattern of cytokine production by macrophages, thus playing an important role in atherogenesis. Azide, the commercial preservative of CRP, may influence its action in vitro. The present study aimed to determine the effects of both isoforms of azide‑containing CRP (mCRP and pCRP) with and without oxLDL on cytokine production by U937‑derived macrophages. U937 monocytes were cultured and differentiated into macrophages and treated with mCRP, pCRP, oxLDL and azide individually and in combination. ELISA were performed to measure the levels of interferon‑γ (IFN‑γ), interleukin (IL)‑4, IL‑6, IL‑10 and tumor necrosis factor (TNF)‑α in culture supernatants collected from U937‑derived macrophages following their respective treatments. Most single and combined treatments, especially in triple combination, were able to downregulate the levels of IFN‑γ and IL‑6 compared with control untreated cells, whilst the combination of mCRP and pCRP increased IL‑4 levels. Regarding IL‑10, except for an increase induced by mCRP, no significant effect was caused by any treatment compared with the control. On the other hand, the levels of TNF‑α were not significantly affected by any treatment except for a decreasing trend that was observed with mCRP/oxLDL treatment compared with control. By contrast, double azide caused a significant decrease in the levels of IFN‑γ and IL‑6. The results of the present study indicated that mCRP, pCRP, oxLD and possibly azide, individually or in different combinations, had the tendency to upregulate the expression of IL‑4 and to downregulate that of the pro‑atherogenic cytokines, IFN‑γ and IL‑6, suggesting that the intima microenvironment serves a crucial role in atherogenesis.

View Figures

View References

1	World Health Organization. Global tuberculosis report 2017. 2017.
2	Ait-Oufella H, Taleb S, Mallat Z and Tedgui A: Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol. 31:969–979. 2011.PubMed/NCBI View Article : Google Scholar
3	Ross R and Agius L: The process of atherogenesis-cellular and molecular interaction: From experimental animal models to humans. Diabetologia. 35 (Suppl 2):S34–S40. 1992.PubMed/NCBI View Article : Google Scholar
4	Gibson MS, Domingues N and Vieira OV: Lipid and non-lipid factors affecting macrophage dysfunction and inflammation in atherosclerosis. Front Physiol. 9(654)2018.PubMed/NCBI View Article : Google Scholar
5	Khallou-Laschet J, Varthaman A, Fornasa G, Compain C, Gaston AT, Clement M, Dussiot M, Levillain O, Graff-Dubois S, Nicoletti A and Caligiuri G: Macrophage plasticity in experimental atherosclerosis. PLoS One. 5(e8852)2010.PubMed/NCBI View Article : Google Scholar
6	Chavez-Sanchez L, Espinosa-Luna JE, Chavez-Rueda K, Legorreta-Haquet MV, Montoya-Diaz E and Blanco-Favela F: Innate immune system cells in atherosclerosis. Arch Med Res. 45:1–14. 2014.PubMed/NCBI View Article : Google Scholar
7	Huang WC, Sala-Newby GB, Susana A, Johnson JL and Newby AC: Classical macrophage activation up-regulates several matrix metalloproteinases through mitogen activated protein kinases and nuclear factor-κB. PLoS One. 7(e42507)2012.PubMed/NCBI View Article : Google Scholar
8	Bentzon JF, Otsuka F, Virmani R and Falk E: Mechanisms of plaque formation and rupture. Circ Res. 114:1852–1866. 2014.PubMed/NCBI View Article : Google Scholar
9	Gronberg C, Nilsson J and Wigren M: Recent advances on CD4⁺ T cells in atherosclerosis and its implications for therapy. Eur J Pharmacol. 816:58–66. 2017.PubMed/NCBI View Article : Google Scholar
10	Kolls JK and Linden A: Interleukin-17 family members and inflammation. Immunity. 21:467–476. 2004.PubMed/NCBI View Article : Google Scholar
11	Tarantino G, Costantini S, Finelli C, Capone F, Guerriero E, La Sala N, Gioia S and Castello G: Is serum interleukin-17 associated with early atherosclerosis in obese patients? J Transl Med. 12(214)2014.PubMed/NCBI View Article : Google Scholar
12	de la Paz Sanchez-Martinez M, Blanco-Favela F, Mora-Ruiz MD, Chavez-Rueda AK, Bernabe-Garcia M and Chavez-Sanchez L: IL-17-differentiated macrophages secrete pro-inflammatory cytokines in response to oxidized low-density lipoprotein. Lipids Health Dis. 16(196)2017.PubMed/NCBI View Article : Google Scholar
13	Hurlimann J, Thorbecke GJ and Hochwald GM: The liver as the site of C-reactive protein formation. J Exp Med. 123:365–378. 1966.PubMed/NCBI View Article : Google Scholar
14	Khreiss T, Jozsef L, Potempa LA and Filep JG: Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation. 109:2016–2022. 2004.PubMed/NCBI View Article : Google Scholar
15	Khreiss T, Jozsef L, Potempa LA and Filep JG: Loss of pentameric symmetry in C-reactive protein induces interleukin-8 secretion through peroxynitrite signaling in human neutrophils. Circ Res. 97:690–697. 2005.PubMed/NCBI View Article : Google Scholar
16	Ji SR, Wu Y, Zhu L, Potempa LA, Sheng FL, Lu W and Zhao J: Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRP(m). FASEB J. 21:284–294. 2007.PubMed/NCBI View Article : Google Scholar
17	Eisenhardt SU, Thiele JR, Bannasch H, Stark GB and Peter K: C-reactive protein: How conformational changes influence inflammatory properties. Cell Cycle. 8:3885–3892. 2009.PubMed/NCBI View Article : Google Scholar
18	Filep JG: Platelets affect the structure and function of C-reactive protein. Circ Res. 105:109–111. 2009.PubMed/NCBI View Article : Google Scholar
19	McFadyen JD, Kiefer J, Braig D, Loseff-Silver J, Potempa LA, Eisenhardt SU and Peter K: Dissociation of C-reactive protein localizes and amplifies inflammation: Evidence for a direct biological role of C-reactive protein and its conformational changes. Front Immunol. 9(1351)2018.PubMed/NCBI View Article : Google Scholar
20	Caprio V, Badimon L, Di Napoli M, Fang WH, Ferris GR, Guo B, Iemma RS, Liu D, Zeinolabediny Y and Slevin M: pCRP-mCRP dissociation mechanisms as potential targets for the development of small-molecule anti-inflammatory chemotherapeutics. Front Immunol. 9(1089)2018.PubMed/NCBI View Article : Google Scholar
21	Singh SK, Suresh MV, Voleti B and Agrawal A: The connection between C-reactive protein and atherosclerosis. Ann Med. 40:110–120. 2008.PubMed/NCBI View Article : Google Scholar
22	Tabuchi M, Inoue K, Usui-Kataoka H, Kobayashi K, Teramoto M, Takasugi K, Shikata K, Yamamura M, Ando K, Nishida K, et al: The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis. J Lipid Res. 48:768–781. 2007.PubMed/NCBI View Article : Google Scholar
23	Zhang JM and An J: Cytokines, inflammation, and pain. Int Anesthesiol Clin. 45:27–37. 2007.PubMed/NCBI View Article : Google Scholar
24	Strober W: Trypan blue exclusion test of cell viability. Curr Protoc Immunol. 111:A3.B.1–A3.B.3. 2015.PubMed/NCBI View Article : Google Scholar
25	Taylor KE and van den Berg CW: Structural and functional comparison of native pentameric, denatured monomeric and biotinylated C-reactive protein. Immunology. 120:404–411. 2007.PubMed/NCBI View Article : Google Scholar
26	Krayem I, Bazzi S and Karam M: The combination of CRP isoforms with oxLDL decreases TNF-α and IL-6 release by U937-derived macrophages. Biomed Rep. 7:272–276. 2017.PubMed/NCBI View Article : Google Scholar
27	Darwich L, Coma G, Peña R, Bellido R, Blanco EJ, Este JA, Borras FE, Clotet B, Ruiz L, Rosell A, et al: Secretion of interferon-gamma by human macrophages demonstrated at the single-cell level after costimulation with interleukin (IL)-12 plus IL-18. Immunology. 126:386–393. 2009.PubMed/NCBI View Article : Google Scholar
28	Voloshyna I, Littlefield MJ and Reiss AB: Atherosclerosis and interferon-γ: New insights and therapeutic targets. Trends Cardiovasc Med. 24:45–51. 2014.PubMed/NCBI View Article : Google Scholar
29	Gadani SP, Cronk JC, Norris GT and Kipnis J: IL-4 in the brain: A cytokine to remember. J Immunol. 189:4213–4219. 2012.PubMed/NCBI View Article : Google Scholar
30	Frodermann V, van Duijn J, van Puijvelde GH, van Santbrink PJ, Lagraauw HM, de Vries MR, Quax PH, Bot I, Foks AC, de Jager SC and Kuiper J: Heat-killed staphylococcus aureus reduces atherosclerosis by inducing anti-inflammatory macrophages. J Intern Med. 279:592–605. 2016.PubMed/NCBI View Article : Google Scholar
31	Yang H, Zhao P and Tian S: Clopidogrel protects endothelium by hindering TNFα-induced VCAM-1 expression through CaMKKβ/AMPK/Nrf2 pathway. J Diabetes Res. 2016(9128050)2016.PubMed/NCBI View Article : Google Scholar
32	Rios FJ, Koga MM, Pecenin M, Ferracini M, Gidlund M and Jancar S: Oxidized LDL induces alternative macrophage phenotype through activation of CD36 and PAFR. Mediators Inflamm. 2013(198193)2013.PubMed/NCBI View Article : Google Scholar
33	Badimon L, Pena E, Arderiu G, Padró T, Slevin M, Vilahur G and Chiva-Blanch G: C-reactive protein in atherothrombosis and angiogenesis. Front Immunol. 9(430)2018.PubMed/NCBI View Article : Google Scholar